INTRODUCTION

Despite significant advancements in the management of pulmonary hypertension (PH), several unmet needs remain. In this podcast episode, Dr. Jean Elwing and Dr. Oksana Shlobin discuss these gaps by focusing on the latest updates from the 7th World Symposium on Pulmonary Hypertension, offering insights into the latest clinical classifications, risk stratifications, and treatment strategies.

Launch Date: November 19, 2024
Release Date: November 19, 2024
Expiration Date: October 31, 2025

TARGET AUDIENCE

Talking PAH activities are designated for healthcare providers who are involved in the clinical care of patients with PAH. This may include physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists.

LEARNING OBJECTIVES

Upon completion of this enduring material, participants should be better able to:

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

• There are no fees for participating in and receiving credit for this enduring material.
• Review the learning objectives and activity information.
• Review all modules associated with this activity.
• Successfully complete the posttest (80% accuracy or better).
• Complete the online evaluation.
• The estimated time to complete this enduring material is 1.25 hour(s).
• Upon successful completion, your AMA or ANCC certificate will be emailed to you. ACPE credit will be submitted to University of Nebraska and posted to CPE Monitor.

ACCREDITATION STATEMENTS

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Practice Point Communications, Inc. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)

 

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.25 ANCC contact hour(s). Nurses should only claim credit for the actual time spent participating in the activity.

 

PHARMACISTS
The University of Nebraska Medical Center designates this knowledge-based activity for 1.25 ACPE contact hour(s). Pharmacists should claim only the credit commensurate with the extent of their participation in the activity.

University of Nebraska Medical Center will report all credit to CPE Monitor after receiving evidence of successful completion of the activity. Successful completion means that you must attend the entire program and complete an evaluation form.

Effective January 1, 2012, all pharmacists are required to provide their NABP e-Profile ID # and Date of Birth (in MMDD format) for issuance of CE credits for any ACPE-accredited CPE sessions. Please go to the following website for full details: https://nabp.pharmacy/cpe-monitor-service.

DISCLOSURE INFORMATION

In compliance with the Standards for Integrity and Independence in Accredited Continuing Education, it is the policy for the accreditor of this accredited continuing education activity to ensure accuracy, balance, objectivity, independence, and scientific rigor in all their educational activities, and to commit to protecting learners from promotion, marketing, and commercial bias. All faculty, planners and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. This enduring material may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of the accredited provider and Practice Point Communications.

DISCLOSURES

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:

PLANNING COMMITTEE DISCLOSURE INFORMATION

The below planning committee members have nothing to disclose:
UNMC: Heidi Brink, PharmD, BCPS, BCCP; Valeta Creason-Wahl, MMP; Heidi Keeler, PhD, MSN/MBA, RN; Renee Paulin, MSN, RN, CWOCN; Brenda Ram, CMP, CHCP; Tammy Wichman, MD
PPC: Bronwyn Boyes; Colleen Goodchild

FACULTY DISCLOSURES
Jean Elwing, MD
Advisory Committee/Board: Acceleron/Merck, Aerovate, Altavant, Bayer, Gossamer Bio, Janssen/Johnson & Johnson, Liquidia, Roivant, United Therapeutics
Research Grant/Investigator: Acceleron/Merck, Actelion/Janssen, Aerovate, Altavant, Bayer, Gossamer Bio, Lung LLC, Pharmosa/Liquidia, Tenax, United Therapeutics
Speaker Bureau, Faculty, Peer Reviewer: Aerovate, United Therapeutics"

Oksana Shlobin, MD
Advisory Committee/Board: Gossamer Bio, Insmed
Consultant: Altavant, Gossamer Bio, Insmed, Janssen, Merck, United Therapeutics
Speaker Bureau, Faculty, Peer Reviewer: United Therapeutics

PRIVACY POLICY

The University of Nebraska Medical Center and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The University of Nebraska Medical Center and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME, ANCC, or ACPE.

The University of Nebraska Medical Center and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

COPYRIGHT INFORMATION

Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:

The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

Supported by independent educational grants from United Therapeutics, a public benefit company, Bayer U.S.; Merck & Co., Inc., Rahway, NJ, USA; and Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson